Language change not allowed if not language of the patent

Darren Smyth
May 16, 2024
#
UPC
#
Recent cases
#
Language

F. Hoffman-La Roche AG, Roche Diabetes Care GmbH v Tandem Diabetes Care, Inc, Tandem Diabetes Care Europe B.V., VitalAire GmbH, Dinno Santé s.a.i., Air Liquide Healthcare Nederland B.V, Rubin Medical ApS UPC_CFI_ 504/2023

Orders of 11 April 2024 (ORD_13986/2024 and ORD_13996/2024) [1]

The claimants (together "Roche") began an infringement claim filed at the Düsseldorf Local Division in the German language against six defendants in respect of EP1970677. Two groups of defendants, Rubin Medical ApS and Tandem Diabetes Care Europe B.V. on the one hand and VitalAire GmbH, Air Liquide Healthcare Nederland B.V, Dinno Santé s.a.i., each group being represented by a shared representative, filed requests for the language of proceedings to be changed from German to English.

This case differs from the previous requests for language change because the language of the patent was German. The judge-rapporteur issued two orders in identical terms, one in respect of the application of each group of defendants, denying the request for language change.

The judge-rapporteur noted that the claimants in the infringement action were entitled to make a choice between English and German as the language of the proceedings, choosing between the possibilities set out in Rule 14(1)(a) RoP (official language of the country hosting the division, in this case German) and Rule 14(1)(b) RoP (another language designated by the country, in this case English). Roche having made this election of the Rule 14(1)(a) option, the only legal basis for a party to request a change in language is Rule 323 RoP. However, this only applies to a change to the language in which the patent was granted.

Since the patent at issue was granted in German, no legal route was seen to change the language to English. Therefore the requests were refused.

[1] https://www.unified-patent-court.org/en/node/706 and https://www.unified-patent-court.org/en/node/708

Recent Case Reports

Scripps mRNA reengineering patent found invalid and not infringed by Comirnaty
08 September 2026
The Local Division Munich invalidated Promosome's licensed mRNA patent over Scripps' codon-optimisation method, then found BioNTech's Comirnaty vaccine would not have infringed the claims even had they been valid.
Fujifilm v Kodak: clarifying the defence of dependent claims and inventive-step combinations at the UPC
27 August 2026
The Court of Appeal gave guidance on defending dependent claims, relying on EPO central limitation during UPC proceedings, and pleading revocation attacks. It also emphasised that inventive-step combinations require a proper pointer to the secondary reference.
Can Reference Numerals Influence Claim Interpretation?
21 August 2026
In T 0903/24, the EPO Board of Appeal relied on reference numerals to interpret disputed claim language, rejecting the patentee's narrower reading and revoking novelty over prior art D2 for the main request.